RNA interference: A promising therapy for gastric cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 14, 2014, Pages 5509-5515

  Felipe, Aledson Vitor ^a,b   de Oliveira, Juliana ^a,b   Chang, Paula Yun Joo ^b   Moraes, Andrea Aparecida De Fatima Souza ^a,c   da Silva, Tiago Donizetti ^a   Tucci Viegas, Vanina Monique ^c   Forones, Nora Manoukian ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Nove de Julho University   (Brazil)

^c DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

Author keywords

Gastric cancer; RNA interference; Therapy

Indexed keywords

CYTOKINE; ONCOPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

BIOSYNTHESIS; CELL TRANSFORMATION; GENETICS; HUMAN; NEOPLASM RECURRENCE, LOCAL; RNA INTERFERENCE; STOMACH NEOPLASMS;

CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HUMANS; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84905985322     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.14.5509     Document Type: Short Survey

References (74)

1. Akhtar J, Wang Z, Zhang ZP, Bi MM (2013). Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo. J Transl Med, 11, 212.
2. Aoyagi K, Kouhuji K, Yano S (2005). VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer, 8, 155-63.
3. Bader AG, Brown D, Winkler M (2010). The promise of microRNA replacement therapy. Cancer Res, 70, 7027-30.
4. Baulcombe DC (2000). Molecular biology. Unwinding RNA silencing. Science, 290, 1108-9.
5. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A (2009). An operational definition of epigenetics. Genes Dev, 23, 781-3.
6. Bilim V, Yuuki K, Itoi T (2008). Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer, 98, 941-9.
7. Brattsand G (2000). Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer, 11, 311-8.
8. Buchet-Poyau K, Courchet J, Le Hir H, et al. (2007). Identification and characterization of human Mex-3 proteins, a novel family of evolutionarily conserved RNA-binding proteins differentially localized to processing bodies. Nucleic Acids Res, 35, 1289-300.
9. Cao C, Lu C, Xu J, et al. (2013). Expression of Rab25 correlates with the invasion and metastasis of gastric cancer. Chin J Cancer Res, 25, 192-9.
10. Chen G, Wang H, Gharib T, et al. (2003). Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics, 11, 107-16.
11. Chia WJ, Tang BL (2009). Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta, 1795, 110-6.
12. Collinge J (2001). Prion diseases of humans and animals: their causes and molecular basis. Ann Rev Neurosci, 24, 519-50.
13. Crabtree JE, Wyatt JI, Trejdosiewicz LK, et al. (1994). Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol, 47, 61-6.
14. Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62.
15. Cui JW, Li Y, Wang C, Yao C, Li W (2012). Knockdown of a proliferation-inducing ligand (PRIL) suppresses the proliferation of gastric cancer cells. Asian Pac J Cancer Prev, 13, 633-6.
16. Deng M, Jing DD, Meng XJ (2013). Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab. Asian Pac J Cancer Prev, 14, 127-31.
17. Dixon MF (1991). Helicobacter pylori and peptic ulceration: histopathological aspects. J Gastroenterol Hepatol, 6, 125-30.
18. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004). EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene, 23, 1448-56.
19. Ferrel JE Jr (2002). Self-perpetuating states in signal transduction: positive feedback, double negative feedback and biostability. Curr Opin Cell Biol, 14, 140-8.
20. Fire A, Xu S, Montgomery MK, et al. (1998). Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature, 391, 806-11.
21. Fish RJ, Kruithof EK (2004). Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol, 5, 9.
22. Friedrich B, Grönberg H, Landström M, Gullberg M, Bergh A (1995). Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate, 11, 102-9.
23. Hahne M, Kataoka T, Schröter M, et al. (1998). APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med, 188, 1185-90.
24. Hannon GJ (2002). RNA interference. Nature, 418, 244-51.
25. Huang J, Shi T, Ma T, et al. (2008). CCDC134, a novel secretory protein, inhibits activation of ERK and JNK, but not p38 MAPK. Cell Mol Life Sci, 65, 338-49.
26. Ireton RC, Chen J (2005). EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets, 5, 149-57.
27. Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin. 61, 69-90.
28. Ji W, Jiang Z (2013). Effect of shRNA-mediated inhibition of Nanog gene expression on the behavior of human gastric cancer cells. Oncol Lett, 2, 367-74.
29. Jiang CG, Lv L, Liu FR, et al. (2012). Connective tissue growth factor is a positive regulator of epithelial-mesenchymal transition and promotes the adhesion with gastric cancer cells in human peritoneal mesothelial cells. Cytokine, 61, 173-80.
30. Jiang H, Zhang X, Luo J, et al. (2012). Knockdown of hMex-3A by small RNA interference suppresses cell proliferation and migration in human gastric cancer cells. Mol Med Report, 6, 575-80.
31. Kuai WX, Wang Q, Yang XZ, et al. (2012). Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol, 18, 979-85.
32. Kunzelmann K (2005). Ion channels and cancer. J Membr Biol, 205, 159-73.
33. Li J, Huang L (2010). Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine, 5, 1483-6.
34. Lin T, Ding YQ, Li JM (2012). Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma. Med Oncol, 2, 878-85.
35. Lindley I, Aschauer H, Seifert JM, et al. (1988). Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophils activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. Proc Natl Acad Sci USA, 85, 9199-203.
36. Lindsley CW (2010). The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem, 10, 458-77.
37. Liu HT, Lu CL (2013). Effect of silencing Bcl-2 expression by small interfering RNA on radiosensitivity of gastric cancer BGC823 cells. Asian Pac J Trop Med, 6, 49-52.
38. Liu L, Liu N, Xu M, et al. (2012). Lentivirus-delivered Krüppel-like factor 8 small interfering RNA inhibits gastric cancer cell growth in vitro and in vivo. Tumour Biol, 33, 53-61.
39. Lorentz O, Duluc I, Arcangelis AD, et al. (1997). Key role of the Cdx2 homeobox gene in extracellular matrix-mediated intestinal cell differentiation. J Cell Biol, 139, 1553-65.
40. Malakar M, Devi KR, Phukan RK (2012). Genetic polymorphism of glutathione S-transferases M1 and T1, tobacco habits and risk of stomach cancer in Mizoram, India. Asian Pac J Cancer Prev, 13, 4725-32.
41. Matsushima K, Morishita K, Yoshimura T, et al. (1988). Molecular cloning of human monocyte-derived neutrophil chemotactic factor (MDNCF) and induction of MDNCF by interleukin-I and tumour necrosis factor. J Exp Med, 167, 1883-93.
42. Matzke MA, Matzke AJ, Pruss GJ, Vance VB (2001). RNA-based silencing strategies in plants. Curr Opin Genet Dev, 11, 221.
43. Melhem RF, Strahler JR, Hailat N, Zhu XX, Hanash SM (1991). Involvement of OP18 in cell proliferation. Biochem Biophys Res Commun, 11, 1649-55.
44. Mizoshita T, Tsukamoto T, Nakanishi H, et al. (2003). Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J Cancer Res Clin Oncol, 129, 727-34.
45. Naldini L, Blömer U, Gallay P, et al. (1996). in vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272, 263-7.
46. Ng W, Loh AX, Teixeira AS, Pereira SP, Swallow DM (2008). Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer, 99, 978-85
47. Ni SZ, Cao HY, Chen Z, Zhu Y, Xu ZK (2012). siRNA interference with a proliferation-inducing ligand gene in the Sgr-7901 gastric carcinoma cell line. Asian Pac J Cancer Prev, 13, 1511-4.
48. Oki E, Baba H, Tokunaga E, et al. (2005). Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer, 117, 376-80.
49. Pan G, Thomson JA (2007). Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res, 1, 42-9.
50. Peng-Fei M, Chen JQ, Wang Z, Liu JL, Li BP (2012). Function of chloride intracellular channel 1 in gastric cancer cells. World J Gastroenterol, 18, 3070-80.
51. Rao DD, Vorhies JS, Senzer N, Nemunaitis J (2009). siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev, 61, 746-59.
52. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ (2009). The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev, 28, 233-45.
53. Sala-Torra O, Gundacker HM, Stirewalt DL, et al. (2007). Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood, 109, 3080-3.
54. Schönherr R (2005). Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol, 205, 175-84.
55. Silberg DG, Swain GP, Suh ER, Traber PG (2000) Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology, 119, 961-71.
56. Sobel A (1991). Stathmin: a relay phosphoprotein for multiple signal transduction? Trends Biochem Sci, 16, 301-5.
57. Suh E, Traber PG (1996). An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol, 16, 619-25.
58. Sulman EP, Tang XX, Allen C, et al. (1997). ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics, 40, 371-4.
59. Thieffry D, Sanchez L (2002). Alternative epigenetic states understood in terms of specific regulatory structures. Ann NY Acad Sci, 981, 135-53.
60. Thiery JP, Acloque H, Huang RY, Nieto MA (2009). Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871-90.
61. Waldrop MM (1989). Catalytic RNA wins chemistry nobel. Science, 246, 325.
62. Wang X, Chen X, Fang J, Yang C (2013). Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol, 6, 586-97.
63. Wang XT, Xie YB, Xiao Q (2012). siRNA targeting of Cdx2 inhibits growth of human gastric cancer MGC-803 cells. World J Gastroenterol, 18, 1903-14.
64. Wang Z, Rao DD, Senzer N, Nemunaitis J (2011). Nemunaitis J. RNA interference and cancer therapy. Pharm Res, 12, 2983-95.
65. Weissmann F, Lyko F (2003). Cooperative interactions between epigenetic modifications and their function in the regulation of chromosome architecture. BioEssays, 25, 792-7.
66. Wight TN (2002). Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol, 14, 617-23.
67. Wilson PA, Plucinski M (2011). A simple Bayesian estimate of direct RNAi gene regulation events from differential gene expression profiles. BMC Genomics, 12, 250.
68. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP (2001). Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res, 61, 8917-23.
69. Yang F, Tuxhorn JA, Ressler SJ, et al. (2005). Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res, 65, 8887-95.
70. Yuan W, Chen Z, Chen Z, et al. (2012). Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma, 59, 105-13.
71. Zabaleta J (2012). Multifactorial etiology of gastric cancer. Methods Mol Biol, 863, 411-35.
72. Zhang Z, Zhang J, Miao L, et al. (2012). Interleukin-11 promotes the progress of gastric carcinoma via abnormally expressed versican. Int J Biol Sci, 8, 383-93.
73. Zhong J, Zhao M, Luo Q, et al. (2013). CCDC134 is down-regulated in gastric cancer and its silencing promotes cell migration and invasion of GES-1 and AGS cells via the MAPK pathway. Mol Cell Biochem, 372, 1-8.
74. Zhou W, Fu XQ, Liu J, Yu HG (2012). RNAi knockdown of the Akt1 gene increases the chemosensitivity of gastric cancer cells to cisplatin both in vitro and in vivo. Regul Pept, 176, 13-21.